What was the overall market valuation of the UK compounding chemotherapy market in 2024?

The overall market valuation was $33.12 Million in 2024. Read More

What is the projected market valuation for the UK compounding chemotherapy market by 2035?

The projected valuation for 2035 is $62.6 Million. Read More

What is the expected CAGR for the UK compounding chemotherapy market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 5.96%. Read More

Which companies are considered key players in the UK compounding chemotherapy market?

Key players include Fresenius Kabi, Baxter International, Civica Rx, and others. Read More

What were the segment valuations for chemotherapeutic and non-chemotherapeutic doses in 2024?

In 2024, chemotherapeutic doses were valued at $20.0 Million, while non-chemotherapeutic doses were valued at $13.12 Million. Read More

How do the valuations for gravimetric and volumetric automated compounding devices compare?

Gravimetric automated compounding devices were valued at $10.0 Million, whereas volumetric devices were valued at $23.12 Million in 2024. Read More

What is the market valuation for sterile and non-sterile compounding in 2024?

In 2024, sterile compounding was valued at $20.0 Million, while non-sterile compounding was valued at $13.12 Million. Read More

What were the valuations for compounding technology with and without robotic arms in 2024?

Compounding technology with robotic arms was valued at $10.0 Million, while that without robotic arms was valued at $23.12 Million. Read More

How does the market for non-sterile compounding compare to sterile compounding in terms of growth?

Non-sterile compounding, valued at $13.12 Million in 2024, appears to grow at a slower rate compared to sterile compounding, which was valued at $20.0 Million. Read More

What trends are anticipated in the UK compounding chemotherapy market as it approaches 2035?

As the market approaches 2035, it may experience growth driven by advancements in technology and increasing demand for personalized medicine. Read More

UK Compounding Chemotherapy Market

ID: MRFR/Pharma/51472-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

UK Compounding Chemotherapy Market Research Report By Dose (Chemotherapeutic, Non-Chemotherapeutics), By Delivery Method (Gravimetric Automated Compounding Device, Volumetric Automated Compounding Device), By Sterility (Sterile, Non-Sterile), and By Technology (With Robotic Arms, Without Robotic Arms) - Growth & Industry Forecast 2025 To 2035

UK Compounding Chemotherapy Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Dose (USD Million)
  1. 4.1.1 Chemotherapeutic
  2. 4.1.2 Non-Chemotherapeutics
2. 4.2 Pharmaceutical, BY Delivery Method (USD Million)
  1. 4.2.1 Gravimetric Automated Compounding Device
  2. 4.2.2 Volumetric Automated Compounding Device
3. 4.3 Pharmaceutical, BY Sterility (USD Million)
  1. 4.3.1 Sterile
  2. 4.3.2 Non-Sterile
4. 4.4 Pharmaceutical, BY Technology (USD Million)
  1. 4.4.1 With Robotic Arms
  2. 4.4.2 Without Robotic Arms
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Fresenius Kabi (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Baxter International (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Civica Rx (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 PharMEDium Services (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Accredo Health Group (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Athenex (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sagent Pharmaceuticals (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 B. Braun Melsungen AG (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY DOSE
3. 6.3 UK MARKET ANALYSIS BY DELIVERY METHOD
4. 6.4 UK MARKET ANALYSIS BY STERILITY
5. 6.5 UK MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY DOSE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY DOSE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY DELIVERY METHOD, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY STERILITY, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY STERILITY, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DOSE, 2025-2035 (USD Million)
  2. 7.2.2 BY DELIVERY METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY STERILITY, 2025-2035 (USD Million)
  4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Pharmaceutical Market Segmentation

Pharmaceutical By Dose (USD Million, 2025-2035)

Chemotherapeutic
Non-Chemotherapeutics

Pharmaceutical By Delivery Method (USD Million, 2025-2035)

Gravimetric Automated Compounding Device
Volumetric Automated Compounding Device

Pharmaceutical By Sterility (USD Million, 2025-2035)

Sterile
Non-Sterile

Pharmaceutical By Technology (USD Million, 2025-2035)

With Robotic Arms
Without Robotic Arms

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”